‘Stabilize’ Is The Message For Teva In North America As It Plots Return To Growth
Israeli Firm Posted Weaker Q4 Numbers Amid Lower Lenalidomide, Truxima Revenues
“The value that generics bring to the healthcare industry, to the hospitals, to society is not reflected in the price that we can sell them at,” Teva told investors, as it outlined plans to mitigate erosion with a slate of big-ticket launches in the US.